⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14683300 | 1.00 | — | — | |
| SCHEMBL31121561 | 1.00 | — | — | |
| SCHEMBL20886323 | 1.00 | — | — | |
| SCHEMBL16925531 | 0.91 | — | — | |
| SCHEMBL5653886 | 0.84 | — | — | |
| SCHEMBL7620587 | 0.84 | — | — | |
| SCHEMBL7630104 | 0.84 | — | — | |
| SCHEMBL21553291 | 0.78 | — | — | |
| SCHEMBL26275648 | 0.71 | ALDH1A1 (0.39) | — | |
| SCHEMBL26275625 | 0.71 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132402-A9 | Compounds and Methods for Modulating UBE3A-ATS | IONIS PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260085313-A1 | COMPOUNDS AND METHODS FOR MODULATING SMN2 | IONIS PHARMACEUTICALS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12534727-B2 | Target to treat a metabolic disease in an individual | UNIVERSIDAD DEL PAÍS VASCO/EUSKAL HERRIKO UNIBERTSITATEA (ES) | 2026-01-27 | — | — | US | disclosed |
| US-20250283081-A1 | Compounds and Methods for Modulating UBE3A-ATS | IONIS PHARMACEUTICALS, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250188476-A1 | COMPOUNDS AND METHODS FOR REDUCING IFNAR1 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025024707-A1 | INHIBITORS OF CDK2/4/6 KINASE | KINNATE BIOPHARMA INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20240401039-A1 | Compounds and Methods for Reducing ATXN2 Expression | IONIS PHARMACEUTICALS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240327838-A1 | MODULATORS OF ENaC EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240301415-A1 | COMPOUNDS FOR MODULATING UNC13A EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240234818-A1 | ELECTROLYTE AND BATTERY CELL, BATTERY, AND ELECTRICAL DEVICE CONTAINING SAME | CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20130338156-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-12-19 | — | — | US | disclosed |
| US-20130164603-A1 | SECONDARY BATTERY | NEC CORPORATION (JP) | 2013-06-27 | — | — | US | disclosed |
| US-8436012-B2 | Imidazopyridin-2-one derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| EP-2576546-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2435432-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2012-04-04 | — | — | EP | disclosed |
| WO-2011149492-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010138588-A9 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | disclosed |
| EP-2308877-A1 | IMIDAZOPYRIDIN-2-ON DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082138-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
| WO-2010138588-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |